Recently the Consortium has had their status upgraded to Takeover Kings with mystery man Andrew Cavenagh branded a ...

Capture One is making it easier to edit exclusively with its app with the new Retouch Faces tool. Plus, it also unveiled ...

Fresh off earning FDA approval for a prefilled syringe version of Vyvgart Hytrulo for at-home administration, argenx is ...

In this article, I switch the focus to exploring how the patent office great again (POGA) movement should prioritize ...

MEDIAIPLUS uses AI to close clinical trial info gaps, offering data tools that match CROs, aid researchers, and support ...

Three former Memphis have been acquitted of state charges, including second-degree murder, in the fatal beating of Tyre ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1 ...

Q1 2025 Earnings Call Transcript May 6, 2025 Day One Biopharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Japanese drugmaker Shionogi said on Wednesday that it will acquire Torii Pharmaceutical , a subsidiary of Japan Tobacco , for ...

CEO Bender also noted progress in the clinical pipeline, including the FIREFLY-2 confirmatory trial, which is on track to be fully enrolled by the first half of 2026. Additionally, the DAY301 program ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.